Veterinary Apothecary highlights new dermatology drug, safety signals
Version 1 — Brief
A new Veterinary Apothecary roundup in dvm360 spotlights a cluster of developments that could affect companion animal prescribing and preventive care, led by the FDA approval of Zenrelia (ilunocitinib) for control of pruritus associated with allergic dermatitis and atopic dermatitis in dogs at least 12 months old. The roundup also points to ongoing movement in vaccines, oncology research, antimicrobial resistance work, compounding oversight, and specialist commentary from dermatology, anesthesia/pain management, and surgery contributors. FDA records show Zenrelia was approved on September 19, 2024, with a boxed warning tied to vaccine timing and immune response, and the agency later issued a January 28, 2025 warning letter to Elanco over promotional claims it said minimized those risks. Related industry updates outside the roundup underscore how broad the current practice landscape is, from new antimicrobial resistance recognition and sequencing diagnostics to practice benchmarking tools and workflow surveys. (animaldrugsatfda.fda.gov; fda.gov)
Why it matters: For veterinary professionals, the bigger story isn’t just that another dermatitis drug is available. It’s that treatment selection now sits even more squarely at the intersection of efficacy, vaccine planning, client communication, pharmacovigilance, and day-to-day practice operations. FDA’s approval summary says dogs receiving Zenrelia should discontinue the drug at least 28 days to 3 months before vaccination and avoid restarting for at least 28 days after vaccination because of risks including inadequate vaccine response and, with modified live vaccines, vaccine-induced disease. At the same time, broader profession updates are reinforcing the need for stronger systems around prescribing, monitoring, and benchmarking: dvm360 recently highlighted updated guidance on compounded medications and the regulatory constraints around patient-specific customization, while VMG and AAHA released an updated veterinary chart of accounts aimed at modernizing financial reporting and practice benchmarking. That makes workflow, reminder systems, and clear conversations with pet parents especially important in itchy-dog cases that also need routine preventive care. (animaldrugsatfda.fda.gov)
What to watch: Watch for how clinics integrate JAK inhibitor use with vaccine scheduling, how teams adapt protocols around compounding and documentation, and whether newer diagnostics, resistance surveillance, and practice-management tools change how small animal hospitals monitor safety, efficiency, and case follow-up. Recent examples include MiDOG’s expanded whole-genome sequencing service for pathogen identification plus resistance-gene detection, and recognition of University of Tennessee dean Paul Plummer, DVM, PhD, for his antimicrobial resistance research leadership. (animaldrugsatfda.fda.gov)